Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial

The Lancet Oncology

Volumn 14, Issue 11, 2013, Pages 1077-1085

  Cunningham, David ^a   Lang, Istvan ^b   Marcuello, Eugenio ^c   Lorusso, Vito ^d   Ocvirk, Janja ^e   Shin, Dong Bok ^f   Jonker, Derek ^g   Osborne, Stuart ^h   Andre, Niko ^h   Waterkamp, Daniel ^h   Saunders, Mark P ⁱ  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e INSTITUTE OF ONCOLOGY   (Slovenia)

^f Gachon University College of Medicine   (South Korea)

^g UNIVERSITY OF OTTAWA   (Canada)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

AGED; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; BLEEDING; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; FEMALE; FISTULA; GEOGRAPHIC DISTRIBUTION; GERIATRIC PATIENT; HAND FOOT SYNDROME; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; KARNOFSKY PERFORMANCE STATUS; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STOMATITIS; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84884700039     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70154-2     Document Type: Article

References (27)

1. Howlader N, Noone AM, Krapcho M, et al, eds. SEER cancer statistics review, 1975-2009 (vintage 2009 populations). (accessed Feb 22, 2013). http://seer.cancer.gov/csr/1975_2009_pops09/.
2. Sehl M, Sawhney R, Naeim A Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005, 11:461-473.
3. Sawhney R, Sehl M, Naeim A Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005, 11:449-460.
4. Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010, 136:737-743.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
6. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706-3712.
7. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
8. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013, 14:29-37.
9. Kabbinavar FF, Hurwitz HI, Yi J, et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009, 27:199-205.
10. Kozloff MF, Berlin J, Flynn PJ, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010, 78:329-339.
11. Bennouna J, Phelip JM, André T, et al. Efficacy and safety at 12 months of 1st line bevacizumab (Bv) plus chemotherapy (CT) in elderly patients (Pt) with metastatic colorectal cancer (mCRC) in daily clinical practice-the CONCERT French observational cohort study. Eur J Cancer 2011, 47(suppl 1). abstr 6113.
12. Kozloff M, Bekaii-Saab TS, Bendell JC, et al. Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS). Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 3625.
13. Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol 2012, 23:1531-1536.
14. Hoffheinz R, Grothe W, Tummes D, et al. Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: mature results from a large community-based observational study. Proc Am Soc Clin Oncol 2012, 30(suppl 4). abstr 566.
15. Venderbosch S, Doornebal J, Teerenestra S, Lemmens W, Punt CJ, Koopman M Outcome of first-line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol 2012, 51:831-839.
16. Bouche O, Steffens C-C, Andre T, et al. Efficacy and safety of treatment with bevacizumab (BEV) + chemotherapy (CT) beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + CT: age subgroup analysis from a randomised phase III intergroup study (ML18147). Ann Oncol 2012, 23(suppl 9). abstr 559P.
17. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer; a personalized approach to clinical decision making. Ann Oncol 2012, 23:2479-2516.
18. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, version 1.2013 National Comprehensive Cancer Network, (accessed Sept 20, 2012). http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
19. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
20. Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. J Clin Oncol 2010, 28:3191-3198.
21. Feliu J, Safont MJ, Salud A, et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 2010, 102:1468-1473.
22. Vrdoljak E, Omrčen T, Boban M, Hrabar A Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer. Anticancer Drugs 2011, 22:191-197.
23. Power DG, Lichtman SM Chemotherapy for the elderly patient with colorectal cancer. Cancer J 2010, 16:241-252.
24. François E, Guérin O, Follana P, Evesque L, Mari V, Aparicio T Use of bevacizumab in elderly patients with metastatic colorectal cancer: review. J Geriatr Oncol 2011, 2:64-71.
25. Wilson PM, Ladner RD, Lenz HJ Predictive and prognostic markers in colorectal cancer. Gastrointestinal Cancer Res 2007, 1:237-246.
26. Naeim A, Lin L, Dichmann R, et al. Phase II study of front-line capecitabine (CAP) and bevacizumab (BEV) in frail and elderly patients with metastatic colorectal cancer (mCRC). American Society of Clinical Oncology Gastrointestinal Cancers Symposium; Orlando, FL, USA, Jan 22-24, 2010. 340.
27. Boehm S, Rothermundt C, Hess D, Joerger M Antiangiogenic drugs in oncology: a focus on drug safety and the elderly-a mini-review. Gerontology 2010, 56:303-309.